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Burn tissue sites are a potential source of bacteremia during debridement surgery. Burn injury is likely to
affect the distribution of antibiotics to tissues, but direct evidence of this is lacking. The aim of this study was
to directly evaluate the influence of burn trauma on the distribution of cephalothin to peripheral tissues. We
used subcutaneous microdialysis techniques to monitor interstitial fluid concentrations of cephalothin in the
burnt and nonburnt tissues of adult patients with severe burns following parenteral administration of 1 g
cephalothin for surgical prophylaxis. Analogous simultaneous studies conducted with healthy adult volunteers
provided reference tissue concentration data. Equivalent tissue exposures were seen for burn and nonburn
sites, giving overall median interstitial cephalothin concentrations (from 0 to 240 min) of 2.84 mg/liter and 3.06
mg/liter, respectively. A lower overall median interstitial cephalothin concentration of 0.54 mg/liter was
observed for healthy individuals, and the patient nonburnt tissue and volunteer control tissue cephalothin
concentrations exhibited significantly different data distributions (P < 0.001; Kolmogorov-Smirnov nonpara-
metric test). The duration of tissue residence for cephalothin was longer for burn patients than for healthy
volunteers. The results demonstrate the potential fallibility of using healthy population models to extrapolate
tissue pharmacodynamic predictions from plasma data for burn patients.
Severe burns and their treatment result in local (17) and
systemic (9, 22) pathophysiological responses that greatly in-
fluence the pharmacokinetics of drugs that are used intraop-
eratively (4, 7, 8, 12, 21). The predominant focus of previous
investigations has been plasma antibiotic concentrations for
the prevention of bacteremia. In burn patients, one of the
sources of bacteremia is from the burn sites, and therefore
consideration of antibiotic concentrations in the tissues be-
comes relevant. Antibiotic concentrations in blood plasma
and interstitial fluid do not necessarily run parallel (10, 18),
and blood-plasma-to-interstitial-fluid exchange is often tis-
sue and drug specific (10, 13). Routine measurement of
tissue antibiotic concentrations may not be practical in the
clinical setting; however, the assessment of a relationship
between plasma and interstitial levels of antibiotic may al-
low us to develop predictive models for tissue antibiotic
concentrations from plasma measurements.
We used subcutaneous microdialysis techniques to monitor
interstitial fluid concentrations of cephalothin in the burnt and
nonburnt tissues of adult patients with severe burns following
parenteral administration of 1 g cephalothin. Analogous stud-
ies conducted in healthy adult volunteers provided reference
tissue concentration data. The study aim was to directly eval-
uate the influence of burn trauma on the distribution of ceph-
alothin to peripheral tissues.
MATERIALS AND METHODS
Study design. This open-label, nonrandomized study of cephalothin distribu-
tion into subcutaneous tissue was conducted with the burn and nonburn sites of
six burn patients and the healthy forearms of five volunteers. Cephalothin was
administered centrally by infusion and monitored peripherally by microdialysis,
with correction for probe recovery by the method of retrodialysis by calibrator
(1). Site and patient matched paired comparisons of burnt and nonburnt tissue
cephalothin microdialysate levels were conducted. A nonpaired comparison of
microdialysate levels from nonburnt tissue sites in burn patients and healthy
volunteers was also undertaken.
Clinical context of the study. Current local practice is for 1 g cephalothin to be
administered 1 hour before debridement to provide broad-spectrum prophy-
lactic cover, predominantly against methicillin- and penicillin-sensitive Staphylo-
coccus aureus strains (19), for which the MIC of cephalothin has been reported
to be 0.2 mg/liter (23). Interstitial concentrations of the MIC (0.2 mg/liter) and
5 MIC (1 mg/liter) were used merely for illustrative purposes in the current
study.
Research context of the study. The microdialysis data for this study were
obtained in conjunction with our previous study reporting plasma levels (4). The
same original cohort of nine burn patients was enrolled in both investigations,
but three patients were withdrawn from the microdialysis study as a consequence
of the considerable practical difficulties of conducting microdialysis in two body
sites throughout eschar debridement and grafting procedures.
Ethical review. The protocol received approval from the Hospital and Uni-
versity of Queensland Human Research Ethics Committees. Written informed
consent was obtained from the legal guardians of enrolled patients and from the
healthy volunteers.
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Patient and volunteer enrollment. Six adult patients with a mean ( standard
deviation [SD]) age of 32 11 years and total body surface area burns of 42%
9% were enrolled in the study. The patients were admitted to the Royal Brisbane
& Women’s Hospital intensive care unit between February 2005 and January
2006 and received eschar debridement and grafting surgery within the first few
days postinjury, during which the studies were conducted. Exclusion criteria
included an age of 18 years, existing bacterial infection, and known infection
with hepatitis A, B, or C virus or human immunodeficiency virus. Patients were
resuscitated during the burn shock phase, using the Parkland formula adjusted to
patients’ requirements (6).
Five volunteers with a mean ( SD) age of 35  10 years were recruited
exclusively from within the research group associated with the study. Exclusion
criteria included an age of 18 years, poor health as assessed by a medical
practitioner, contraindicated medications, and a known allergy to penicillin.
Burn patient and healthy volunteer study protocols. Patient studies were
conducted during debridement and grafting procedures within 4 days of trauma
(mean posttrauma delay before grafting, 2.3  1.1 days; mean surgery duration,
5.4  1.3 h). First-dose cephalothin was investigated in all subjects. Patients
received 1 g cephalothin in 10 ml 0.9% saline over 5 min through a dedicated
lumen of a central venous catheter; volunteers received the same dose regimen
intravenously into a forearm vein. Burn patient microdialysis sites were selected
for anticipated ease of access during debridement surgery in body areas that were
not expected to be required as skin graft donor sites or scheduled for eschar
debridement at this procedure. Full-thickness burn sites and adjacent nonburnt
skin areas in the neck/shoulder and groin/thigh areas were used. After insertion,
probes were held in place with a surgical stitch and then, in the operating theater,
were covered with protective sterile gauze and stapled to avoid dislodgment
during the debridement procedure.
All volunteers received 1 g cephalothin in 10 ml 0.9% saline over 5 min
through a peripheral venous catheter inserted into the basilic vein at the elbow.
The microdialysis site for volunteers was the radial forearm on the side con-
tralateral to the one used for the administration of cephalothin. Patient and
volunteer microdialysis sites were anesthetized with 1% lignocaine (Xylocaine;
AstraZenica, United Kingdom) before probe insertion. The probe was held in
place with Tegaderm (3M Health Care, MN). CMA 60 microdialysis probes
(CMA, Stockholm, Sweden) were perfused with aseptically prepared 0.9% saline
containing 2 mg/liter cefazolin at a flow rate of 1.6 l per minute from a 1-ml
syringe, using a Graseby MS16 24-h syringe driver (Smiths Group Plc, London,
United Kingdom). Microdialysis probes were perfused for up to 30 min prior to
insertion to remove the preservative buffer. Probe perfusate was collected into
sterile CMA collection vials, which were changed at 20-min intervals and stored
on ice. Probe perfusate eluted prior to cephalothin administration was discarded.
Experiments began upon commencement of cephalothin infusion, whose timing
was dictated by the anticipated surgery commencement time, in accordance with
local therapeutic guidelines for surgical site infection prophylaxis (19). Prior to
storage at 20°C, microdialysis perfusate was carefully transferred to pre-
weighed reduced-volume 300-l polypropylene autosampler vials (Phenomenex,
CA), using a refrigerated centrifuge. This enabled probe outflow volume mea-
surement, ensured optimal sample storage conditions, and greatly facilitated
subsequent sample handling.
Antibiotic analysis. Microdialysate analysis by liquid chromatography-tandem
mass spectrometry used an API 2000 mass spectrometer (Applied Biosystems) in
positive electrospray mode (cephalothin Q1/Q3  397/152.2 m/z, cefazolin
Q1/Q3  455.2/156 m/z, and benzylpenicillin Q1/Q3  335.1/160 m/z). Chro-
matographic separation on a 50- by 2-mm Gemini C18 column (Phenomenex)
was achieved at a flow rate of 300 l/min with a binary gradient (5 to 12 min
postinjection) of 0% to 76% acetonitrile in 0.1% formic acid-water, using a
Shimadzu high-performance liquid chromatography system, and gave retention
times of 13.2, 12.0, and 12.6 min for cephalothin, cefazolin, and benzylpenicillin
(internal standard), respectively. Calibration curves (0.1 to 16 g/ml) were linear
(r2  0.99). For sample preparation, 5 l microdialysate and 70 l benzylpeni-
cillin (200 ng/ml in 0.9% saline) were mixed in polypropylene vials, and 50 l was
used for injection.
Microdialysis recovery correction. The method of continuous retrodialysis by
calibrator (1) was used to calculate microdialysis recovery for each data point,
using measurements of cefazolin (calibrator) loss into tissue across the semiper-
meable membrane according to the following equation:
Recoveryin situ Cin  CoutCin calibrator
where Cin and Cout were the concentrations of cefazolin (calibrator) in the
microdialysis perfusion fluid inflow and the microdialysis perfusate outflow,
respectively. The mean recovery for each microdialysis probe was subsequently
used to calculate cephalothin interstitial fluid concentrations.
Microdialysis data pairing. A small number of burn patient microdialysis
samples were lost as a result of temporary impairment of microdialysis probe
perfusion. To ensure true pairing of the burn and nonburn microdialysis data,
values corresponding to a lost sample pair were omitted.
Data analysis and presentation. Mean ( SD) interstitial fluid concentrations
of cephalothin and non-protein-bound (unbound) plasma cephalothin concen-
trations are presented as log-linear plots. Target microdialysis sample collection
times were plotted. Minor variations in microdialysis sample times were unavoid-
able; 20-min-interval target times fell within the 95% confidence interval (95%
CI) of each mean sample time. Linear interpolation of unbound plasma ceph-
alothin concentrations permitted their temporal matching with the actual micro-
dialysis sampling intervals. Unbound cephalothin data were calculated from
patient and volunteer total plasma cephalothin values collected as described
previously (4). Prestudy plasma samples were used for measurements of percent
plasma protein binding of cephalothin. Briefly, 500 l of 100-g/ml cephalothin
in plasma was incubated (37°C, 30 min) and ultracentrifuged (12,000 g, 20 min)
through 30-kDa-nominal-cutoff membrane devices (Amicon YM30; Millipore
Corporation, Billerica, MA) to give a filtrate yield of approximately 25% of the
original volume, which was analyzed by high-performance liquid chromatography
(4). The times above the MIC of cephalothin against S. aureus (TMICS. aureus)
and five times the S. aureus MIC (T  5 MICS. aureus) were obtained for a
published MIC of 0.2 mg/liter (23). Values for T  MICS. aureus and T  5
MICS. aureus were derived from terminal-phase log-linear interpolation of
weighted (1/y) biexponential fits (C  Ae	t  Be
t) to each interstitial con-
centration-time data set. T  MICS. aureus and T  5 MICS. aureus data are
presented as column dot plots overlaid with mean and 95% CI marks. Compu-
tation made use of Microsoft Excel 2003 (Microsoft Corporation) for data
analysis, Graphpad Prism for Windows, version 4.03 (Graphpad Software Inc.),
for regression analysis, SPSS for Windows, version 15.0.1 (SPSS Inc.), for
statistical analysis, and the R computing language to compile all plots (R
Development Core Team [http://www.R-project.org]). Statistical testing of
T  MICS. aureus values was done by Student’s t test, applying pairing only to
burn-nonburn paired comparisons. The highly robust Kolmogorov-Smirnov
nonparametric distribution-independent test (KS test) was used for direct
comparisons of site-itemized interstitial cephalothin data, unbound cephalo-
thin data, and microdialysis probe recovery data.
RESULTS
Patient and volunteer demographics. Table 1 shows the pa-
tient and volunteer demographic data, plasma protein binding
of cephalothin, and patient surgery details. The two study co-
horts were well matched in terms of body size and age.
Paired comparison of interstitial cephalothin concentra-
tions in burnt and nonburnt tissues. Figure 1 shows the
patient matched paired comparison of mean interstitial
cephalothin concentrations in burnt and nonburnt subcuta-
TABLE 1. Subject demographics and patient surgery details
Characteristic
Mean  SD for group
Patients Volunteers
Age (yr) 32 11 35  10
Height (m) 1.76 0.08 1.73  0.12
Weight (kg) 82.5 14 68  13
TBSAa (%) 41.6  8.5
Posttrauma delay (days) 2.3  1.1
Surgery duration (h) 5.4  1.3
Vol (liters) of fluid administeredb
Intravenous crystalloid 3.55 2.37
Albumin 0.67 0.23
Blood products 2.59 1.97
Plasma bindingc (%) 58.0  9.0 70.8  2.4
a Total burn surface area (sum of second and third degree burn areas).
b Itemized fluid volumes administered over 8 hours.
c Plasma protein binding of cephalothin.
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neous tissues in burn patients during debridement surgery.
Equivalent tissue exposures were seen for burn and nonburn
sites, giving overall median interstitial cephalothin concen-
trations (from 0 to 240 min) of 2.84 mg/liter and 3.06 mg/
liter, respectively, with only 23% of the burn site data being
1 mg/liter (5 MICS. aureus). Burn site interstitial cephalo-
thin concentrations of 0.2 mg/liter (MICS. aureus) were not
observed in any patient within 240 min. No significant dif-
ference between the burn site and nonburn site interstitial
cephalothin concentration data distributions was observed
(P  0.133; KS test).
Comparison of interstitial cephalothin concentrations in
nonburnt tissues of patients and healthy volunteers. Figure 1
allows comparison of mean interstitial cephalothin concen-
trations in nonburnt tissues of burn patients and forearm
sites of healthy volunteers. Nonburnt tissue exposure to
cephalothin was higher for burn patients than for healthy
individuals, giving overall median interstitial cephalothin
concentrations (from 0 to 240 min) of 3.06 mg/liter and 0.54
mg/liter, respectively. The patient nonburnt tissue and vol-
unteer control tissue cephalothin concentrations exhibited
significantly different data distributions (P  0.001; KS test).
Higher peak concentrations were seen for nonburn sites
than for controls, and the levels were maintained for longer
times, such that only 7% of the nonburn site patient data
were lower than 0.2 mg/liter (MICS. aureus), compared with
28% of the healthy control data. Similarly, 20% of the
nonburn site patient data were lower than 1 mg/liter (5
MICS. aureus), compared with 64% of the healthy control
data.
Comparison of interstitial cephalothin T > MICS. aureus
values for burnt and nonburnt tissues of patients and con-
trol tissues of healthy volunteers. Figure 2a shows the T 
MICS. aureus data for interstitial cephalothin in each study
subject grouped by tissue site and overlaid by grouped
means and 95% CI. Nonburnt tissue sites in burn patients
gave significantly higher T  MICS. aureus values than did
forearm sites in healthy volunteers (control), with times
(mean  95% CI) of 336  74 min and 160  31 min,
respectively (P  0.001; nonpaired t test). Patient matched
paired comparison of interstitial cephalothin T  MICS. aureus
data revealed no mean difference between burn sites and
nonburn sites (P  0.148; paired t test), with burn sites
giving a T  MICS. aureus (mean  95% CI) of 285  78 min.
FIG. 1. Semilogarithmic plot of mean plus SD interstitial cephalo-
thin concentrations for healthy volunteers (filled squares), burn patient
nonburn sites (open circles), and burn patient burn sites (filled circles).
FIG. 2. Column dot plots of T  MICS. aureus (a) and T  5
MICS. aureus (b) data grouped by tissue site and overlaid with mean and
95% CI marks. T  MICS. aureus and T  5 MICS. aureus values were
derived from terminal-phase log-linear interpolation of weighted (1/y)
biexponential fits (C  Ae
	t  Be

t) to each interstitial concentra-
tion-time data set. Control and nonburn means differed significantly
for both T  MICS. aureus (a) and T  5 MICS. aureus (b) data (P 
0.001; nonpaired t test).
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Comparison of interstitial cephalothin T > 5 MICS. aureus
values for burnt and nonburnt tissues of patients and control
tissues of healthy volunteers. Figure 2b shows the T  5
MICS. aureus data for interstitial cephalothin in each study sub-
ject grouped by tissue site and overlaid by grouped mean and
95% CI. Nonburnt tissue sites in burn patients gave signifi-
cantly higher T 5MICS. aureus values than did forearm sites
in healthy volunteers (control), with times (mean 95% CI) of
219  53 min and 96  38 min, respectively (P  0.001;
nonpaired t test). Patient matched paired comparison of inter-
stitial cephalothin T  5 MICS. aureus data revealed no mean
difference between burn sites and nonburn sites (P  0.135;
paired t test), with burn sites giving a T  5 MICS. aureus
(mean  95% CI) of 191  50 min.
Comparison of maximal unbound cephalothin concentra-
tions in the plasma and interstitial compartments for patients
and healthy volunteers. Maximal plasma cephalothin concen-
trations are observed in burn patients upon completion of
infusion (4). The mean  SD postinfusion (5 min) unbound
plasma cephalothin concentrations for healthy volunteers and
burn patients were 17.6 5.4 mg/liter and 38.7 19.7 mg/liter,
respectively. For healthy volunteers, maximal mean interstitial
concentrations of unbound cephalothin were captured in the
first microdialysis collection (0 to 20 min) and gave a mean 
SD of 8.6  5.3 mg/liter. The second microdialysis collection
(20 to 40 min) captured maximal mean interstitial concentra-
tions of unbound cephalothin for burn patients and gave values
of 8.9  4.2 mg/liter and 14.5  15.4 mg/liter for nonburn and
burn sites, respectively.
Comparison of interstitial cephalothin and unbound plasma
cephalothin in burnt and nonburnt tissues of patients and
control tissues of healthy volunteers. Interstitial cephalothin
and unbound plasma cephalothin concentrations for patients
and volunteers are presented in Fig. 3. Volunteer control in-
terstitial cephalothin and unbound cephalothin concentrations
ran parallel (Fig. 3a) and gave equivalent data distributions
(P  0.4; KS test). Burn patient nonburn site (Fig. 3b) and
burn site (Fig. 3c) interstitial cephalothin concentration pro-
files lagged behind unbound plasma cephalothin concentra-
tions, with higher concentrations being maintained within the
interstitium. Patient nonburn and burn interstitial cephalothin
concentration data distributions were both distinct from the
corresponding unbound plasma cephalothin data distribution
(P  0.001; KS test).
Ratio of interstitial cephalothin to unbound plasma ceph-
alothin in burnt and nonburnt tissues of patients and control
tissues of healthy volunteers. Patient matched paired burn and
nonburn site investigations gave overall (0 to 240 min) mean
SD interstitial/unbound plasma cephalothin ratios of 8.56 
12.0 and 7.77  10.3, respectively. No significant difference in
the data distributions of the interstitial/unbound plasma ceph-
alothin ratio data was seen between the burn and nonburn sites
(P  0.64; KS test). The ratios of interstitial cephalothin to
unbound plasma cephalothin concentrations were consistently
lower for the volunteers than for the nonburn sites of burn
patients (P  0.001; KS test), giving an overall (0 to 240 min)
mean  SD ratio of 2.0  1.2.
Microdialysis probe recovery details. Probe recovery data
for patients and volunteers were constant with time. The mean
microdialysis recovery data for all patient (n  122) and vol-
unteer (n  54) microdialysis measurements were 44%  20%
and 68%  16%, respectively. Patient and volunteer microdi-
alysis probe recovery data distributions differed significantly
(P  0.001; KS test). Significantly different microdialysis probe
recovery data distributions were also observed within the burn
patient cohort, with mean burn site (n  61) and nonburn site
(n  61) recoveries being 38%  18% and 50%  19%,
respectively (P  0.01; KS test). The relative order of micro-
dialysis probe recoveries was as follows: healthy volunteer 
patient nonburn site  patient burn site.
DISCUSSION
The principal findings of this study were that a single bolus
dose of 1 g of cephalothin gave equivalent cephalothin kinetics
in the subcutaneous tissues of burn sites and nonburn sites of
burn patients and that interstitial cephalothin concentrations
were maintained longer in burn patients than in healthy vol-
unteers. The MIC of cephalothin against methicillin- and pen-
icillin-sensitive Staphylococcus aureus strains was exceeded for
over 4 h in burn patient tissues.
This study is the first to apply microdialysis to a comparison
of interstitial antibiotic concentrations in a surgical patient
group and a nonsurgical volunteer group. It is also the first
reported patient matched paired comparison of burn site and
nonburn site interstitial antibiotic concentrations in an acute-
phase burn patient population. The reported data are of direct
clinical relevance, having been derived using established mi-
crodialysis techniques coupled with robust and effective cali-
bration methods (retrodialysis by calibrator) (1) and validated
analysis protocols. Stringent selection criteria were applied to
the burn cohort; we studied first-dose cephalothin kinetics
during debridement surgery within 4 days of trauma in patients
with 30% total body surface area burns and no signs of
infection.
We previously published guidance on prophylaxis of tran-
sient bacteremia, indicating the need for intraoperative redos-
ing of cephalothin during prolonged surgery for maintenance
of effective plasma concentrations (4). Burnt tissue is one
source of bacteremia during burn debridement, and therefore
consideration of antibiotic concentrations in the tissues is also
relevant. The results of the current study suggest that the
pathophysiological determinants of altered antibiotic distribu-
tion in burn patients actually create a favorable environment
for antimicrobial action in tissue sites. Evidence for this can be
seen from the plots of interstitial cephalothin T  MICS. aureus
data displayed in Fig. 2 and from the comparisons of interstitial
cephalothin time courses for nonburn sites in patients and
volunteers given in Fig. 1. The underlying causes of prolonged
tissue residence times of cephalothin in burn patient tissues
appear to be complex in nature, affecting both burn and non-
burn sites to similar extents (Fig. 1 and 2).
Accurate measurement of interstitial drug concentrations by
microdialysis is reliant on appropriate calibration methodology
(2). The current investigation used the method of continuous
retrodialysis by calibrator (1) and met all relevant technical
prerequisites (1, 2). It is of considerable interest that the mi-
crodialysis probe recovery data were affected by the tissue site.
The relative order of microdialysis probe recoveries was as
follows: healthy volunteer control site  patient nonburn site 
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patient burn site. Low microdialysis probe recoveries result
from a small loss of calibrator (cefazolin) from the microdialy-
sis probe and may be a consequence of impaired tissue clear-
ance of cefazolin from burnt and, to a lesser extent, nonburnt
tissues.
The rates of disappearance for unbound cephalothin con-
centrations in plasma and interstitial fluid appeared to be par-
allel in the volunteer group, consistent with an elimination
clearance with a slight delay in the interstitial profile, reflecting
a delay in the transfer between the plasma and interstitial
compartments. In contrast, the unbound profiles for the inter-
stitial fluid were significantly higher than the unbound plasma
concentrations, but the disappearance rates were similar after
40 min for the burn sites and after 100 min for the nonburn
sites (Fig. 3). The longer delay between unbound cephalothin
concentration equivalence in the plasma and interstitium ob-
served for burn patients than for healthy volunteers is consis-
tent with reports of impaired full-thickness burn tissue vascular
FIG. 3. Mean plus SD interstitial cephalothin (open circles) and unbound plasma cephalothin (closed circles) concentrations for healthy
volunteers (a), patient nonburn sites (b), and patient burn sites (c). Error bars for interstitial and unbound plasma cephalothin values are displaced
to the left and right, respectively, for 20-min data only. Temporal matching of plasma values to microdialysis sample times was achieved by linear
interpolation. The unbound plasma cephalothin value was calculated with prestudy plasma protein binding data for each subject.
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perfusion (3). The similar increases in the area under the curve
for unbound interstitial levels in patient nonburnt and burnt
tissue sites probably arose in part from bound cephalothin
(plasma protein binding in burn patients, 58%  9%) being
carried into the tissues with the albumin that undergoes ex-
travasation, as reported for patients with severe edema (11).
All recruited patients exhibited systemic inflammatory re-
sponse syndrome, which results in microvascular leakage of
plasma proteins and fluid into the interstitium. Furthermore,
systemic endothelial dysfunction is exacerbated during burn
debridement (20) as a result of localized release of inflamma-
tory factors from manipulated burn tissue (14). Increased areas
under the curve for unbound interstitial levels in the nonburnt
and burnt tissue sites are also in keeping with prior published
observations of increased antibiotic distribution volumes and
third-space sequestration seen in patients with severe edema
(15, 16), an increased extravascular space, and impaired or
delayed lymphatic drainage (5).
This study has shown equivalent distributions of cephalothin
to burnt and nonburnt tissue sites and illustrated the mainte-
nance of elevated tissue levels for longer in burn patients than
in healthy volunteers. The results demonstrate the potential
fallibility of extrapolating tissue pharmacodynamic predictions
from plasma data for burn patients in the same way as those
extrapolated between compartments in the healthy population.
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